Skip to main content

Sotalol Hydrochloride AF and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with Sotalol Hydrochloride AF (sotalol).

Moderate

Sotalol Alcohol (Ethanol)

Moderate Drug Interaction

Sotalol and ethanol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

Sotalol Multivitamins With Minerals

Moderate Drug Interaction

Using sotalol together with multivitamin with minerals may decrease the effects of sotalol. Separate the administration times of sotalol and multivitamin with minerals by at least 2 hours. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

Sotalol High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Moderate Potential Hazard, Low plausibility

beta-blockers - hyperlipidemia

Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles. Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers. Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.

References

  1. Rossner S, Weiner L (1983) "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol, 24, p. 573-7
  2. Valimaki M, Maass L, Harno K, Nikkila EA (1986) "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol, 30, p. 17-20
  3. Disler LJ, Joffe BI, Seftel HC (1988) "Massive hypertriglyceridemia associated with atenolol." Am J Med, 85, p. 586-7
  4. Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV (1987) "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol, 27, p. 475-80
  5. Darga LL, Hakim MJ, Lucas CP, Franklin BA (1991) "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol, 67, p. 590-6
  6. Weiner L, Rossner S (1983) "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand, 677, p. 153-7
  7. Ferrara LA, Marotta T, Scilla A, et al. (1984) "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol, 26, p. 331-4
  8. Pasotti C, Capra A, Fiorella G, et al. (1982) "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol, 13, s435-9
  9. Carlson LA, Ribacke M, Terent A (1987) "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol, 24, s61-2
  10. Samuel P, Chin B, Schoenfeld BH, et al. (1987) "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol, 24, s63-4
  11. Terent A, Ribacke M, Carlson LA (1989) "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol, 36, p. 347-50
  12. Sasaki J, Saku K, Ideishi M, et al. (1989) "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther, 11, p. 219-24
  13. Szollar LG, Meszaros I, Tornoci L, et al. (1990) "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol, 15, p. 911-7
  14. Leren P, Foss PO, Nordvik B, Fossbakk B (1988) "The effect of enalapril and timolol on blood lipids." Acta Med Scand, 223, p. 321-6
  15. (2002) "Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories
  16. (2002) "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc
  17. (2002) "Product Information. Normodyne (labetalol)." Schering Corporation
  18. (2002) "Product Information. Trandate (labetalol)." Glaxo Wellcome
  19. (2002) "Product Information. Corgard (nadolol)." Bristol-Myers Squibb
  20. (2001) "Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories
  21. (2001) "Product Information. Blocadren (timolol)." Merck & Co., Inc
  22. Northcote RJ, Packard CJ, Ballantyne D (1986) "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta, 158, p. 187-91
  23. Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA (1983) "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol, 21, p. 73-6
  24. (2001) "Product Information. Cartrol (carteolol)." Abbott Pharmaceutical
  25. (2001) "Product Information. Kerlone (betaxolol)." Searle
  26. (2001) "Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals
  27. (2001) "Product Information. Betapace (sotalol)." Berlex Laboratories
  28. (2001) "Product Information. Zebeta (bisoprolol)." Lederle Laboratories
  29. Safran AB, Simona F, Sansonetti A, Pometta D, James R (1994) "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol, 117, p. 683
  30. (2001) "Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation
  31. Clucas A, Miller N (1988) "Effects of acebutolol on the serum lipid profile." Drugs, 36 Suppl 2, p. 41-50
  32. (2001) "Product Information. Levatol (penbutolol)." Reed and Carnrick
  33. Kasiske BL, Ma JZ, Kalil RS, Louis TA (1995) "Effects of antihypertensive therapy on serum lipids." Ann Intern Med, 122, p. 133-41
  34. Lind L, Pollare T, Berne C, Lithell H (1994) "Long-term metabolic effects of antihypertensive drugs." Am Heart J, 128, p. 1177-83
  35. Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K (1994) "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther, 32, p. 660-4
  36. (2001) "Product Information. Coreg (carvedilol)." SmithKline Beecham
  37. Lithell H, Andersson PE (1997) "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol, 52, p. 13-7
  38. Gordon NF, Scott CB, Duncan JJ (1997) "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol, 79, p. 1065-9
  39. (2007) "Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals
View all 39 references

Sotalol Hydrochloride AF drug interactions

There are 607 drug interactions with Sotalol Hydrochloride AF (sotalol).

Sotalol Hydrochloride AF disease interactions

There are 20 disease interactions with Sotalol Hydrochloride AF (sotalol) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer